First Trust Nasdaq Pharmaceuticals ETF
FTXH
20 hedge funds and large institutions have $19.4M invested in First Trust Nasdaq Pharmaceuticals ETF in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.
128% more capital invested
Capital invested by funds: $8.52M → $19.4M (+$10.9M)
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
32.74% more ownership
Funds ownership: 48.93% → 81.66% (+33%)
18% more funds holding
Funds holding: 17 → 20 (+3)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$6.33M |
| 2 |
AWM
AE Wealth Management
Topeka,
Kansas
|
+$4.21M |
| 3 |
Truist Financial
Charlotte,
North Carolina
|
+$918K |
| 4 |
WFA
WMG Financial Advisors
Knoxville,
Tennessee
|
+$850K |
| 5 |
Jane Street
New York
|
+$397K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$724K |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$538K |
| 3 |
LJAC
L.J. Altfest & Co
New York
|
-$251K |
| 4 |
LPL Financial
San Diego,
California
|
-$239K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$60.5K |
FTXH Hedge Fund Activity: Q2 2022 in Review
20 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q2 2022, worth a combined $19.4M — up 128% from $8.52M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new FTXH positions and 4 closed out — a net gain of 3 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was D.A. Davidson & Co, opening a new position worth an estimated $6.33M. The largest seller was Susquehanna International Group, cutting an estimated $724K.
- 20 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q2 2022, up from 17 in Q1 2022.
- Funds reported $19.4M of First Trust Nasdaq Pharmaceuticals ETF stock for Q2 2022, up 128% quarter-over-quarter.
- 7 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q2 2022 and 4 closed out, a net change of +3 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q2 2022 was D.A. Davidson & Co, an estimated $6.33M added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q2 2022 was Susquehanna International Group, an estimated $724K sold.
Based on aggregated 13F filings for Q2 2022.